胆道閉鎖症の乳児における門脈造瘻術後の静脈内免疫グロブリン(IVIG)の安全性試験 (PRIME)
胆道閉鎖症の乳児における門脈造瘻術後の静脈内免疫グロブリン(IVIG)療法の第1/2A相試験
The Children Liver Disease Research and Education Network (ChiLDREN) is conducting a clinical trial to determine the feasibility, acceptability, tolerability and safety profile of IVIG treatment administered to infants after hepatic portoenterostomy (HPE) for biliary atresia, as well as investigate preliminary evidence of activity and explore mechanisms of action.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
In this multicenter prospective phase 1/2A open label trial, the feasibility, tolerability and safety of intravenous immunoglobulin (IVIG) therapy following hepatic portoenterostomy (HPE) will be assessed in 29 infants with biliary atresia (BA), efficacy will be estimated and exploratory mechanistic research studies will be performed. After written consent is obtained from the parent or guardian, the subject will be enrolled and will receive three intravenous doses of IVIG at designated intervals over the first 60 days following HPE and will be followed for 360 days after enrollment. Blood will also be obtained during this study to assess potential mechanisms by which the IVIG may alter or reduce bile duct inflammation and injury and improve bile flow. All infants in this trial will also be treated with standardized doses of other routine standard-of-care treatments for BA during this trial (ursodeoxycholic acid, trimethoprim-sulfamethoxasole, and fat-soluble vitamin supplements). This routine clinical care will not be modified by participation in this study. Subjects in this study will not receive corticosteroid therapy for treatment of biliary atresia, as this is of unproven benefit at the present time.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Children's Healthcare of Atlanta
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
Pittsburgh、Pennsylvania、アメリカ、15213
- Children's Hospital at Pittsburgh
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- Hospital for Sick Children
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Infant under 120 days old with established diagnosis of BA. Subjects in this trial must start treatment within 3-5 days of the Kasai procedure and be part of a prospective study of the natural history of biliary atresia also being conducted by ChiLDREN (http://www.clinicaltrials.gov/ct/show/NCT00061828?order=3).
- Standard HPE operation has been performed for BA within the previous 3 days
- Post-conception age ≥ 36 weeks at time of enrollment
- Weight at enrolment ≥ 2000 gm
- Written informed consent to participate in the study obtained within 3 days of completion of HPE.
Exclusion Criteria:
- Laparoscopic HPE or "gall bladder Kasai" (cholecysto-portostomy) surgery was performed
- Biliary atresia splenic malformation syndrome (presence of asplenia, polysplenia or double spleen)
- History of a hypercoagulable disorder
- Renal Disease defined as serum creatinine > 1.0 mg/dl prior to enrollment or presence of complex renal anomalies found on imaging
- Evidence of congestive heart failure or fluid overload
- Presence of significant systemic hypertension for age (defined as persistent systolic blood pressure ≥112 mmHg measured on at least 3 occasions following HPE)
- Infants whose mother is known to have human immunodeficiency virus infection
- Infants whose mother is known to be serum HBsAg or hepatitis C virus antibody positive
- Previous treatment with intravenous immunoglobulin therapy or corticosteroid therapy
- Previous treatment with any other investigational agent
- History of allergic reaction to any human blood product infusion
- Infants with other severe concurrent illnesses, such as neurological, cardiovascular, pulmonary, metabolic, endocrine, and renal disorders, that would interfere with the conduct and results of the study
- Any other clinical condition that is a contraindication to the use of IVIG
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:IVIG active treatment
Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE |
All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility of IVIG Treatment
時間枠:60 days post-HPE
|
Percentage of subjects for whom administration of IVIG is feasible, defined as the successful administration (at least 80% of each dose) of all 3 doses of IVIG |
60 days post-HPE
|
|
Acceptability of IVIG
時間枠:60 days post-HPE
|
Percentage of subjects for whom the study is acceptable, defined as the ability of the subject's family or guardian to allow intravenous line placements, blood draws, and other study procedures for the study subjects. |
60 days post-HPE
|
|
Serious Adverse Events
時間枠:360 days post-HPE
|
Percentage of subjects with any serious adverse events (SAEs) prior to liver transplant |
360 days post-HPE
|
|
Level 3-5 Toxicity
時間枠:360 days post-HPE
|
Percentage of subjects with any level 3, 4, or 5 toxicity (per NCI CTEP grading system) |
360 days post-HPE
|
|
Adverse Events
時間枠:360 days post-HPE
|
Percentage of subjects with other expected adverse events |
360 days post-HPE
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Good Bile Drainage at 90 Days Post-HPE
時間枠:90 days post-HPE
|
Percentage of subjects who survive 90 days after HPE with both their native liver and serum total bilirubin <1.5 mg/dL at 90 days after HPE |
90 days post-HPE
|
|
Good Bile Drainage at 180 Days Post-HPE
時間枠:180 days post-HPE
|
Percentage of subjects who survive 180 days after HPE with both their native liver and serum total bilirubin <1.5 mg/dL at 180 days after HPE |
180 days post-HPE
|
|
Good Bile Drainage at 360 Days Post-HPE
時間枠:360 days post-HPE
|
Percentage of subjects who survive 360 days after HPE with both their native liver and serum total bilirubin <1.5 mg/dL at 360 days after HPE |
360 days post-HPE
|
|
Transplant-free Survival
時間枠:360 days post-HPE
|
Percentage of subjects who survive with their native liver at 360 days after HPE. |
360 days post-HPE
|
|
Circulating Regulatory T-Cells, Inflammatory Cytokines, and Specific Autoantibodies.
時間枠:Over 360 days after HPE
|
Percentage and absolute number of Tregs (CD4+CD25+FoxP3+), CD3/4 T cells, CD3/8 T cells, NK cells (CD56), NK T cells (CD3/56), CD19/20 B cells, macrophages (CD14/11b), and neutrophils; plasma levels of anti-enolase antibody; and plasma cytokine levels (Th1/Th2 multiplex and IL17) |
Over 360 days after HPE
|
協力者と研究者
スポンサー
スポンサー
捜査官
捜査官
- スタディチェア:Ronald Sokol, MD、Children's Hospital Colorado
- スタディディレクター:Ed Doo, MD、National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)
- スタディディレクター:Averell Sherker, MD、National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (推定)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- P007 PRIME
- U01DK062456 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。